References
- Dai C, Li D, Gong L, et al. Curcumin ameliorates furazolidone-induced DNA damage and apoptosis in human hepatocyte L02 cells by inhibiting ROS production and mitochondrial pathway. Molecules. 2016;21(8):1061.
- Lewkowski J, Rogacz D, Rychter P. Hazardous ecotoxicological impact of two commonly used nitrofuran-derived antibacterial drugs: Furazolidone and nitrofurantoin. Chemosphere. 2019;222:381–390.
- Timperio AM, Kuiper HA, Zolla L. Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003;33(2):153–167.
- De Angelis I, Rossi L, Pedersen JZ, et al. Metabolism of furazolidone: Alternative pathways and modes of toxicity in different cell lines. Xenobiotica. 1999;29(11):1157–1169.
- Huttner A, Verhaegh EM, Harbarth S, et al. Nitrofurantoin revisited: a systematic review and Meta-analysis of controlled trials. J Antimicrob Chemother. 2015;70(9):2456–2464.
- Le VVH, Olivera C, Spagnuolo J, et al. In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria. BMC Microbiol. 2020;20(1):5–11.
- Shetnev A, Baykov S, Kalinin S, et al. 1,2,4-oxadiazole/2-imidazoline hybrids: Multi-target-directed compounds for the treatment of infectious diseases and cancer. Int J Mol Sci. 2019;20(7):1699.
- Ali BH. Pharmacological, therapeutic and toxicological properties of furazolidone: Some recent research. Vet Res Commun. 1999;23(6):343–360.
- Zuma NH, Aucamp J, N'Da DD. An update on derivatisation and repurposing of clinical nitrofuran drugs. Eur J Pharm Sci. 2019;140:105092.
- Chadfield MS, Hinton MH. Effects of furazolidone pretreatment of Salmonella enteritidis PT4 at Sub- and suprainhibitory concentrations on phagocytosis and intracellular survival in chicken macrophages. Vet Immunol Immunopathol. 2004;100(1-2):81–97.
- Song C, Qian X, Zhu Y, et al. Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice. Helicobacter. 2019;24(4):e12591–12.
- McCracken RJ, Kennedy DG. Furazolidone in chicken: case study of an incident of widespread contamination. Br Poult Sci. 2013;54(6):704–712.
- Zhuge L, Wang Y, Wu S, et al. Furazolidone treatment for Helicobacter Pylori infection: a systematic review and Meta-analysis. Helicobacter. 2018;23(2):e12468–11.
- Khademi F, Sahebkar A. An updated systematic review and Meta-Analysis on the Helicobacter pylori antibiotic resistance in Iran (2010-2020)). Microb Drug Resist. 2020;26(10):1186–1194.
- Mokhtare M, Hosseini V, Fakheri HT, et al. Comparison of quadruple and triple furazolidone containing regimens on eradication of helicobacter pylori. Med J Islam Repub Iran. 2015;29:195.
- Sun Y, Tang S, Jin X, et al. Opposite effects of JNK and p38 MAPK signaling pathways on furazolidone-stimulated S phase cell cycle arrest of human hepatoblastoma cell line. Mutat Res. 2013;755(1):24–29.
- Deng S, Tang S, Dai C, et al. P21(Waf1/Cip1) plays a critical role in furazolidone-induced apoptosis in HepG2 cells through influencing the caspase-3 activation and ROS generation. Food Chem Toxicol. 2016;88:1–12.
- Otta DA, De Araújo F, De Rezende B, et al. Identification of anti- trypanosoma cruzi lead compounds. 2018. p. 1–13.
- Corre I, Paris F, Huot J. The p38 pathway, a major pleiotropic Cascade that transduces stress and metastatic signals in endothelial cells. Oncotarget. 2017;8(33):55684–55714.
- Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005;15(1):11–18.
- Gut AM, Vasiljevic T, Yeager T, et al. Salmonella infection - prevention and treatment by antibiotics and probiotic yeasts: a review,. Microbiology (Reading)). 2018;164(11):1327–1344.
- Tubo NJ, Jenkins MK. CD4+ T cells: Guardians of the phagosome. Clin Microbiol Rev. 2014;27(2):200–213.
- Abimannan T, Peroumal D, Parida JR, et al. Oxidative stress modulates the cytokine response of differentiated Th17 and Th1 cells,” free radic. Free Radic Biol Med. 2016;99:352–363.